Earnings Call Snapshots: Vanda, Jazz, WuXi, Lundbeck
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanda Pharmaceuticals is gearing up to launch its atypical antipsychotic Fanapt in the fourth quarter, after its approval in May; meanwhile Jazz Pharmaceuticals is looking ahead to commercial plans for its fibromyalgia candidate JZP-6 (sodium oxybate), with an NDA filing expected this year.